Eledon Pharmaceuticals (ELDN)

Data Update From Phase 1b Trial Shows Continued Tegoprubart Benefits


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
June 4, 2024
Report ID: 26792
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Eledon Pharmaceuticals
Eledon Pharmaceuticals
Healthcare
Biotechnology
Ticker
ELDN
Current Price
$2.61 -4.4%
Market Cap
$100.5M
Price Target
Refer to Report
Volume
107.4K
52wk Range
$1.07 - $3.349
Related Research Reports
6/4/2024

Data Update From Phase 1b Trial Shows Continued Tegoprubart Benefits
Data Update From Phase 1b Trial Shows Continued Tegoprubart Benefits (ELDN)
5/8/2024

Islet Cell Transplant Patient Treated As Kidney Data Presentation Is Announced
Islet Cell Transplant Patient Treated As Kidney Data Presentation Is Announced (ELDN)
3/22/2024

First Transplant Of A Pig Kidney Uses Tegoprubart To Prevent Immune Rejection
First Transplant Of A Pig Kidney Uses Tegoprubart To Prevent Immune Rejection (ELDN)
11/10/2023

3Q23 Reported With Review Of Clinical Progress
3Q23 Reported With Review Of Clinical Progress (ELDN)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy